| Metric | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 54 | Distressed valuation offset by structural profitability headwinds; dividend sustainability at risk | 6–12M |
| SA Quality/Value Composite | C | 48 | Forward PE 4.27 suggests deep discount, but negative EPS (–$13.19) invalidates traditional valuation; high dividend yield (11.26%) unsustainable without earnings recovery | 3–6M |
| Zacks Earnings Momentum | F | 18 | Negative EPS, no forward guidance disclosed, YoY revenue decline –3.62%; no earnings date announced | 1–3M |
| Institutional & Smart Money Flow | B– | 62 | Market cap $1.44B (micro–small cap); average volume 2.80M shares suggests limited liquidity; 52W return –62.84% indicates institutional exit or capitulation | 1–3M |
| Growth Sustainability & Moat | D– | 32 | Pharmaceutical OTC/generic exposure in mature, low-margin category; revenue contraction YoY; no disclosed TTM revenue or growth acceleration signals | 6–12M |
| Valuation & Safety (Pre-Penalty) | C+ | 56 | Forward PE 4.27 is historically cheap; 52W high $28.22 vs. current $10.43 (–63%) suggests value trap risk; beta 0.52 indicates lower volatility but not protective in distressed scenarios | 3–6M |
| Penalty Overlay (Fundamental Risk) | –18 pts | Applied | Negative earnings, dividend yield unsustainable without FCF confirmation, no earnings guidance, data gaps on TTM revenue and earnings date | Immediate |
| CONFIDENCE SCORE | C– | 52 | Data gaps on earnings date, TTM revenue, and target consensus limit precision; reliant on price action and dividend yield as valuation crutch | 6–12M |
| Volatility & Drawdown Risk | C | 50 | Beta 0.52 (lower systematic risk) but 52W drawdown –62.84% and thin liquidity create idiosyncratic risk; dividend cuts would trigger sharp repricing | 1–3M |
| Crowding Risk Flag | Low | N/A | Sub-$1.5B market cap, microcap fundamentals; limited institutional coverage; value trap characteristics deter fresh accumulation | Ongoing |
Perrigo (PRGO) operates in the mature pharmaceutical OTC and generic drug space, competing against larger diversified pharma and consumer health peers (e.g., Church & Dwight, Edgewell, smaller generics players). At $1.44B market cap and declining revenues (–3.62% YoY), PRGO is structurally smaller and more exposed to margin compression in the OTC category. The company's negative EPS (–$13.19) and unsustainably high dividend yield (11.26%) suggest either temporary distress or structural impairment. Peer multiples in the pharma/consumer health space typically trade 12–18x forward earnings for growth; PRGO's forward PE 4.27 is a 75%+ discount—classic value-trap territory without earnings inflection evidence.
| Horizon | Base Case | Key Inflection Points | Risk Level |
|---|---|---|---|
| 1–3 Months | Stabilization test; dividend maintained but under scrutiny. Price range $9.50–$11.50 unless earnings surprise or dividend cut announced. Negative momentum (–62.84% YoY) pressures new institutional inflows. | Earnings announcement (date not disclosed); FCF adequacy; analyst coverage changes | High |
| 6–12 Months | Earnings recovery or dividend retrenchment. If revenue stabilizes and EPS turns positive by Q2 2027, rerating to 8–10x forward PE plausible ($20–30 range). If not, 30–50% downside to sub-$7 as dividend cut cascades. | Full-year guidance; M&A/portfolio moves; margin improvement or competitor pressures; refinancing events | Elevated |
PRGO is a value trap masquerading as a dividend opportunity. The stock has collapsed 63% from 52-week highs, trading at a 75% discount to historical averages—hallmark symptoms of structural distress rather than cyclical undervaluation. Negative EPS and declining revenues point to operational deterioration in a competitive, low-margin OTC pharma segment. The 11.26% dividend yield is unsustainable without demonstrated FCF generation; any cut would trigger a sharp repricing downward. The company's lack of earnings guidance, missing TTM revenue disclosure, and absent earnings date weaken institutional confidence and limit analyst coverage depth.
Upside scenario (30% probability): Cost restructuring + revenue stabilization + dividend maintenance leads to EPS recovery and PE rerating to 8–10x by mid-2027, driving price to $20–30.
Base case (50% probability): Dividend cut to 5–6% yield within 6 months; stock consolidates at $8–12; institutional outflows accelerate.
Downside scenario (20% probability): Dividend suspended, debt concerns emerge, stock falls to $5–7 within 12 months.
Recommendation: Avoid for most equity portfolios. Suitable only for distressed/value specialists with conviction in turnaround and high risk tolerance.
PRGO Stock Analysis & Forecast
Is PRGO a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
PRGO Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, PRGO shows balanced risk-reward characteristics.
Should You Buy PRGO Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in PRGO.